Drug Trial Radar · NCT05139602
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy
Last checked: Nov 20, 2026Latest source record: Feb 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
210
Actual
Start
Dec 28, 2021
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Dec 1, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in areas of the skin such as under the breasts, under armpits, inner thighs, groin and buttocks. Despite the clinical benefit anti-tumor necrosis factor (TNF) therapy offers to patients with HS, there remains a significant unmet medical need for patients who fail to achieve adequate benefit with anti-TNF therapy. This study will compare lutikizumab (ABT-981) versus placebo for the treatment of adult participants with moderate to severe HS who have failed anti-TNF therapy. Lutikizumab (ABT-981) is an investigational drug being developed for the treatment of HS. In the Main Study, participants will be put in 1 of 4 groups, called treatment arms. There is a 1 in 4 chance that participants will be assigned to placebo. Around 160 adult participants with moderate to severe HS who have failed anti-TNF therapy will be enrolled in the study at approximately 50 sites worldwide. In the Sub-study, participants will be put in 1 of 2 groups, called treatment arms. Both arms will receive treatment at different dosing intervals. Around 40 adult participants with moderate to severe HS who are naïve to biologic therapy will be enrolled in the study at approximately 20 sites. In the Main Study, participants will receive subcutaneous injections of lutikizumab (ABT-981) or placebo every week for 16 weeks. In the Sub-study, participants will receive subcutaneous injections of lutikizumab (ABT-981) every week for the first 15 weeks, then either every week or every other week for 36 weeks. There will be an optional Long Term Extension (LTE) for participants who completed Week 52 of the Sub-study and, as confirmed by the investigator, have shown a therapeutic benefit to study drug. Participants would then received lutikizumab using the same assigned dosing regimen as that from Period 2 of the Sub-study for an additional 104 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires and diaries.
Conditions
- Hidradenitis Suppurativa
Interventions
LutikizumabBiological
Subcutaneous Injection
PlaceboDrug
Subcutaneous Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving Hidradenitis Suppurative Clinical Response (HiSCR)Time frame: Week 16
- Number of Participants with Adverse Events (AEs)Time frame: Up to Approximately Week 68
Locations
54 sites in 8 countries. Site status is shown where the registry gives one.
Medical Dermatology Specialists /ID# 240641
Phoenix, Arizona
Mayo Clinic - Scottsdale /ID# 241030
Scottsdale, Arizona
Burke Pharmaceutical Research /ID# 240811
Hot Springs, Arkansas
UCSF Fresno /ID# 240903
Fresno, California
Medderm Associates /ID# 240729
San Diego, California
Clinical Trials Research Institute /ID# 240642
Thousand Oaks, California
CCD Research, PLLC /ID# 240728
Cromwell, Connecticut
Skin Care Research Boca Raton /ID# 240758
Boca Raton, Florida
Apex Clinical Trials /ID# 248558
Brandon, Florida
GSI Clinical Research, LLC /ID# 240901
Margate, Florida
Florida International Rsrch cr /ID# 240902
Miami, Florida
Park Avenue Dermatology, PA /ID# 240807
Orange Park, Florida
Duplicate_TruDerm Dermatology of Wellington /ID# 240780
Wellington, Florida
Dawes Fretzin, LLC /ID# 240701
Indianapolis, Indiana
Beth Israel Deaconess Medical Center /ID# 240683
Boston, Massachusetts
Revival Research Institute, LLC /ID# 241020
Troy, Michigan
MediSearch Clinical Trials /ID# 240810
Saint Joseph, Missouri
Washington University-School of Medicine /ID# 240797
St Louis, Missouri
Advanced Dermatology of the Midlands /ID# 249750
Omaha, Nebraska
Duplicate_Skin Specialists, PC /ID# 240804
Omaha, Nebraska
Schweiger Dermatology, P.C. /ID# 240900
New York, New York
Mount Sinai Doctors Dermatology /ID# 241588
New York, New York
Montefiore Medical Center /ID# 240853
The Bronx, New York
Essential Medical Research, LLC /ID# 241807
Tulsa, Oklahoma
Center for Clinical Studies - Houston (Binz) /ID# 240692
Houston, Texas
Duplicate_Paratus Clinical Research Woden /ID# 240605
Phillip, Australian Capital Territory, Australia
Momentum Clinical Research /ID# 240911
Darlinghurst, New South Wales, Australia
Premier Specialist /ID# 241288
Kogarah, New South Wales, Australia
Veracity Clinical Research /ID# 241096
Woolloongabba, Queensland, Australia
Beacon Dermatology Inc /ID# 240741
Calgary, Alberta, Canada
Wiseman Dermatology Research /ID# 240738
Winnipeg, Manitoba, Canada
Lima's Excellence in Allergy and Dermatology Research Inc /ID# 240814
Hamilton, Ontario, Canada
Ryan Clinical Research Inc /ID# 247986
Newmarket, Ontario, Canada
Dre Angelique Gagne-Henley M.D. inc. /ID# 240739
Saint-Jérôme, Quebec, Canada
Havelklinik /ID# 240874
Berlin, Germany
Klinikum Ruhr Univ Bochum /ID# 240870
Bochum, Germany
Staedtisches Klinikum Dessau /ID# 240871
Dessau, Germany
Universitaetsklinikum Hamburg-Eppendorf /ID# 240873
Hamburg, Germany
Duplicate_Universitaetsklinikum Erlangen /ID# 240872
Erlangen, Bavaria, Germany
General Hospital of Thessaloniki Hippokrateio /ID# 240697
Thessaloniki, Greece
Showing 40 of 54 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.